Table 1.

List of glycoconjugate vaccines licensed for use in the USA. OMP, outer membrane protein complex of the B11 strain of Neisseria meningitidis serogroup B. ^a , ^b

Vaccine (trade name/manufacturer)	Licensed in	Pathogen	Type, serotype coverage/repeating unit structure	Carrier protein	Saccharide size/linkage
Pedvax‐Hib/Merck Sharp & Dohme Corp (Kenilworth, NJ, USA)	1990	Haemophilus influenzae	Type b/PRP, →3)‐β‐d‐Ribf‐(1→1)‐d‐Ribitol‐(5→OPO3→	OMP	Medium/random
ActHib/Sanofi Pasteur SA (Marcy L’Etoile,France)	1993	Haemophilus influenzae	Type b/PRP, →3)‐β‐d‐Ribf‐(1→1)‐d‐Ribitol‐(5→OPO3→	TT	Large/random
Menactra/Sanofi Pasteur Inc. (Swiftwater, PA, USA)	2005	Neisseria meningitidis	A/→6)‐α‐d‐ManpNAc(3/4OAc)‐(1→OPO3→ C/→9)‐α‐d‐Neup5Ac(7/8OAc)‐(2→ Y/→6)‐α‐d‐Glcp‐(1→4)‐α‐d‐Neup5Ac(9OAc)‐(2→ W‐135/→6)‐α‐d‐Galp‐(1→4)‐α‐d‐Neup5Ac(9OAc)‐(2→	DT	Medium/random
Hiberix/GSK (Rixensart, Belgium)	2009	Haemophilus influenzae	Type B/PRP, →3)‐β‐d‐Ribf‐(1→1)‐d‐Ribitol‐(5→OPO3→	TT	Large/random
Menveo/GSK (Sovicille, Italy)	2010	Neisseria meningitidis	A/→6)‐α‐d‐ManpNAc(3/4OAc)‐(1→OPO3→ C/→9)‐α‐d‐Neup5Ac(7/8OAc)‐(2→ Y/→6)‐α‐d‐Glcp‐(1→4)‐α‐d‐Neup5Ac(9OAc)‐(2→ W‐135/→6)‐α‐d‐Galp‐(1→4)‐α‐d‐Neup5Ac(9OAc)‐(2→	CRM197	Medium/random
Prevnar 13/Pfizer (Philadelphia, PA, USA)	2010	Streptococcus pneumoniae	1/→3)‐α‐d‐AATGalp‐(1→4)‐α‐d‐GalpA(2/3OAc)‐(1→3)‐α‐d‐GalpA‐(1→ 3/→3)‐β‐d‐GlcpA‐(1→4)‐β‐d‐Glcp‐(1→ 4/→3)‐β‐d‐ManpNAc‐(1→3)‐α‐l‐FucpNAc‐(1→3)‐α‐d‐GalpNAc‐(1→4)‐α‐d‐Galp2,3(S)Pyr‐(1→ 5/→4)‐β‐d‐Glcp‐(1→4)‐[α‐l‐PnepNAc‐(1→2)‐β‐d‐GlcpA‐(1→3)]‐α‐l‐FucpNAc‐(1→3)‐β‐d‐Sugp‐(1→ 6A/→2)‐α‐d‐Galp‐(1→3)‐α‐d‐Glcp‐(1→3)‐α‐l‐Rhap‐(1→3)‐d‐Rib‐ol‐(5→ OPO3→ 6B/→2)‐α‐d‐Galp‐(1→3)‐α‐d‐Glcp‐(1→3)‐α‐l‐Rhap‐(1→4)‐d‐Rib‐ol‐(5→ OPO3→ 7F/→6)‐[β‐d‐Galp‐(1→2)]‐α‐d‐Galp‐(1→3)‐β‐l‐Rhap2Ac‐(1→4)‐β‐d‐Glcp‐(1→3)‐[α‐d‐GlcpNAc‐(1→2)‐ α‐l‐Rhap(1→4)]‐β‐d‐GalpNAc‐(1→ 9V/→4)‐α‐d‐GlcpA(2/3OAc)‐(1→3)‐α‐d‐Galp‐(1→3)‐β‐d‐ManpNAc(4/6OAc)‐(1→4)‐β‐d‐Glcp‐(1→4)‐α‐d‐Glcp‐(1→ 14/→4)‐β‐d‐Glcp‐(1→6)‐[β‐d‐Galp‐(1→4)]‐β‐d‐GlcpNAc‐(1→3)‐β‐d‐Galp‐(1→ 18C/→4)‐β‐d‐Glcp‐(1→4)‐[α‐d‐Glcp(6OAc)‐(1→2)]‐[Gro‐(1→OPO3→3)]‐β‐d‐Galp‐(1→4)‐a‐d‐Glcp‐(1→3)‐β‐l‐Rhap‐(1→ 19A/→4)‐β‐d‐ManpNAc‐(1→4)‐α‐d‐Glcp‐(1→3)‐α‐l‐Rhap‐(1→ OPO3→ 19F/→4)‐β‐d‐ManpNAc‐(1→4)‐α‐d‐Glcp‐(1→2)‐α‐l‐Rhap‐(1→ OPO3→ 23F/→4)‐β‐d‐Glcp‐(1→4)‐[α‐l‐Rhap‐(1→2)]‐[Gro‐(2→ OPO3→3)]‐β‐d‐Galp‐(1→4)‐β‐l‐Rhap‐(1→	CRM197	Large/random
MenQuadfi/Sanofi Pasteur Inc. (Swiftwater, PA, USA)	2020	Neisseria meningitidis	A/→6)‐α‐d‐ManpNAc(3/4OAc)‐(1→OPO3→ C/→9)‐α‐d‐Neup5Ac(7/8OAc)‐(2→ Y/→6)‐α‐d‐Glcp‐(1→4)‐α‐d‐Neup5Ac(9OAc)‐(2→ W‐135/→6)‐α‐d‐Galp‐(1→4)‐α‐d‐Neup5Ac(9OAc)‐(2→	TT	Large‐medium/random

^a https://www.fda.gov/vaccines‐blood‐biologics/vaccines/vaccines‐licensed‐use‐united‐states

^b For Hib (Haemophilus influenzae type b), the table does not include multivalent formulations active also toward other diseases.